Literature DB >> 18379437

Cholinergic neuronal and axonal abnormalities are present early in aging and in Alzheimer disease.

Changiz Geula1, Nicholas Nagykery, Alexander Nicholas, Chuang-Kuo Wu.   

Abstract

A large body of evidence indicates that basal forebrain cholinergic neurons are selectively vulnerable to degeneration early in Alzheimer disease (AD). Recent studies, however, demonstrate reductions in cortical activity of the cholinergic enzyme choline acetyltransferase only in late stages of AD. To address this apparent contradiction, we compared abnormalities in magnocellular basal forebrain cholinergic neurons and their axons in nondemented young (<65 years; n = 6), nondemented old (>65 years; n = 7), pathologically mild (n = 5), and pathologically severe (n = 5) AD cases. Cholinergic axon abnormalities (i.e. thickened fibers and ballooned terminals) were evident in nondemented middle-aged cases, increased in nondemented old cases, and reduced in density in severe AD. This suggests that loss of cortical cholinergic axons in AD occurs preferentially in fibers with these abnormalities. Paired helical filament 1-immunoreactive pretangles and tangles were observed as early as the third decade prior to their appearance in entorhinal/perirhinal cortex; they were increased in mild and severe AD. These results indicate that basal forebrain cholinergic neuron abnormalities are present very early in aging and in the course of AD. Therefore, despite the morphologic alterations, choline acetyltransferase activity, but not necessarily normal neuron functions, may be preserved.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18379437      PMCID: PMC3243760          DOI: 10.1097/NEN.0b013e31816a1df3

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  50 in total

1.  Loss of basal forebrain P75(NTR) immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease.

Authors:  Elliott J Mufson; Shuang Y Ma; John Dills; Elizabeth J Cochran; Sue Leurgans; Joanne Wuu; David A Bennett; Syed Jaffar; Michelle L Gilmor; Alan I Levey; Jeffrey H Kordower
Journal:  J Comp Neurol       Date:  2002-02-04       Impact factor: 3.215

2.  Evolution of Alzheimer's disease-related cytoskeletal changes in the basal nucleus of Meynert.

Authors:  I Sassin; C Schultz; D R Thal; U Rüb; K Arai; E Braak; H Braak
Journal:  Acta Neuropathol       Date:  2000-09       Impact factor: 17.088

3.  Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.

Authors:  Roger Bullock; Jacques Touchon; Howard Bergman; Giuseppe Gambina; Yunsheng He; Günter Rapatz; Jennifer Nagel; Roger Lane
Journal:  Curr Med Res Opin       Date:  2005-08       Impact factor: 2.580

4.  Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer's disease.

Authors:  E J Mufson; S Y Ma; E J Cochran; D A Bennett; L A Beckett; S Jaffar; H U Saragovi; J H Kordower
Journal:  J Comp Neurol       Date:  2000-11-06       Impact factor: 3.215

5.  Loss of calbindin-D28k from aging human cholinergic basal forebrain: relation to neuronal loss.

Authors:  Changiz Geula; Jing Bu; Nicholas Nagykery; Leonard F M Scinto; Jennifer Chan; Jeffrey Joseph; Robert Parker; Chuang-Kuo Wu
Journal:  J Comp Neurol       Date:  2003-01-06       Impact factor: 3.215

6.  Cholinergic plasticity in hippocampus of individuals with mild cognitive impairment: correlation with Alzheimer's neuropathology.

Authors:  Milos D Ikonomovic; Elliott J Mufson; Joanne Wuu; Elizabeth J Cochran; David A Bennett; Steven T DeKosky
Journal:  J Alzheimers Dis       Date:  2003-02       Impact factor: 4.472

7.  Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment.

Authors:  Steven T DeKosky; Milos D Ikonomovic; Scot D Styren; Laurel Beckett; Stephen Wisniewski; David A Bennett; Elizabeth J Cochran; Jeffrey H Kordower; Elliott J Mufson
Journal:  Ann Neurol       Date:  2002-02       Impact factor: 10.422

8.  Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons.

Authors:  D M Hartley; D M Walsh; C P Ye; T Diehl; S Vasquez; P M Vassilev; D B Teplow; D J Selkoe
Journal:  J Neurosci       Date:  1999-10-15       Impact factor: 6.167

Review 9.  A clinical overview of cholinesterase inhibitors in Alzheimer's disease.

Authors:  Martin Farlow
Journal:  Int Psychogeriatr       Date:  2002       Impact factor: 3.878

10.  Selective cytotoxicity of intracellular amyloid beta peptide1-42 through p53 and Bax in cultured primary human neurons.

Authors:  Yan Zhang; Richard McLaughlin; Cynthia Goodyer; Andréa LeBlanc
Journal:  J Cell Biol       Date:  2002-01-28       Impact factor: 10.539

View more
  73 in total

1.  Cerebrospinal fluid levels of Aβ42 relationship with cholinergic cortical activity in Alzheimer's disease patients.

Authors:  Alessandro Martorana; Zaira Esposito; Francesco Di Lorenzo; Viola Giacobbe; Giulia Maria Sancesario; Giulia Bucchi; Sonia Bonnì; Sergio Bernardini; Roberto Sorge; Giuseppe Sancesario; Giorgio Bernardi; Carlo Caltagirone; Giacomo Koch
Journal:  J Neural Transm (Vienna)       Date:  2012-03-09       Impact factor: 3.575

2.  Progression of tau pathology in cholinergic Basal forebrain neurons in mild cognitive impairment and Alzheimer's disease.

Authors:  Laurel Vana; Nicholas M Kanaan; Isabella C Ugwu; Joanne Wuu; Elliott J Mufson; Lester I Binder
Journal:  Am J Pathol       Date:  2011-09-23       Impact factor: 4.307

Review 3.  Turning on the Light Within: Subcortical Nuclei of the Isodentritic Core and their Role in Alzheimer's Disease Pathogenesis.

Authors:  Panos Theofilas; Sara Dunlop; Helmut Heinsen; Lea Tenenholz Grinberg
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

Review 4.  Where attention falls: Increased risk of falls from the converging impact of cortical cholinergic and midbrain dopamine loss on striatal function.

Authors:  Martin Sarter; Roger L Albin; Aaron Kucinski; Cindy Lustig
Journal:  Exp Neurol       Date:  2014-05-05       Impact factor: 5.330

5.  MRI-based volumetric measurement of the substantia innominata in amnestic MCI and mild AD.

Authors:  S George; E J Mufson; S Leurgans; R C Shah; C Ferrari; L deToledo-Morrell
Journal:  Neurobiol Aging       Date:  2009-12-14       Impact factor: 4.673

6.  Early endosomal abnormalities and cholinergic neuron degeneration in amyloid-β protein precursor transgenic mice.

Authors:  Jennifer H K Choi; Gurjinder Kaur; Matthew J Mazzella; Jose Morales-Corraliza; Efrat Levy; Paul M Mathews
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

Review 7.  Alzheimer's disease as homeostatic responses to age-related myelin breakdown.

Authors:  George Bartzokis
Journal:  Neurobiol Aging       Date:  2009-09-22       Impact factor: 4.673

8.  A new tacrine-melatonin hybrid reduces amyloid burden and behavioral deficits in a mouse model of Alzheimer's disease.

Authors:  Carlos Spuch; Desiree Antequera; M Isabel Fernandez-Bachiller; M Isabel Rodríguez-Franco; Eva Carro
Journal:  Neurotox Res       Date:  2009-09-23       Impact factor: 3.911

Review 9.  Amyloid-Beta and Phosphorylated Tau Accumulations Cause Abnormalities at Synapses of Alzheimer's disease Neurons.

Authors:  Ravi Rajmohan; P Hemachandra Reddy
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

10.  Alterations of Ca²⁺-responsive proteins within cholinergic neurons in aging and Alzheimer's disease.

Authors:  David Riascos; Alexander Nicholas; Ravand Samaeekia; Rustam Yukhananov; M-Marsel Mesulam; Eileen H Bigio; Sandra Weintraub; Ling Guo; Changiz Geula
Journal:  Neurobiol Aging       Date:  2013-12-25       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.